Crescent Biopharma, Inc.

Stage 3 · Topping · week 3

As of Oct 22, 2026, Crescent Biopharma is in Stage 3, the topping phase, now in week 3 (since Oct 6, 2026). It closed at $13.14, 51.3% below its 52-week high and below its 200-day average, which is rising.

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. More about the company

$13.14

-0.23% today

$488M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is CBIO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 16w

S2 14w

S4 24w

S4 31w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 16w → S1 3w → S2 14w → S3 6w → S4 24w → S1 12w → S4 4w → S3 2w → S2 3w → S3 4w → S4 31w → S1 6w → S4 11w → S1 2w → S2 11w → S3 10w → S2 4w → S3 2w current

Total tracked: 166 weeks across 18 stage runs.

CBIO among Biotechnology173rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…173	CBIOCrescent Biopharma, Inc.	Stage 3 · wk 3	58	−7.4%

vs 52W High

-51.3%

$8.94 lo$26.98 hi

51.3% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 3

1w13w26w

Week 3, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-17.0%

200 DMA: $15.82 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.43x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-7.4%

-19.4%

-48.9%

YTD

+18.6%

+3.9%

Scan Membership

Breakout Watch

Latest: 2025-03-10

6 appearances in last 60 days. First seen: 2020-08-28.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 3 · Vol 0.43x

2026-10-21S3

Wk 3 · Vol 0.58x

2026-10-20S3

Wk 3 · Vol 0.80x

2026-10-19S3

Wk 2 · Vol 0.62x

2026-10-16S3

Wk 2 · Vol 0.56x

2026-10-15S3

Wk 2 · Vol 0.80x

2026-10-14S3

Wk 2 · Vol 0.77x

2026-10-13S3

Wk 2 · Vol 0.53x

2026-10-12S3

Wk 1 · Vol 0.41x

2026-10-09S3

Wk 1 · Vol 0.93x

2026-10-08S3

Wk 1 · Vol 0.80x

2026-10-07S3

Wk 1 · Vol 2.90x

Moving averages & range

50 DMA

$16.05

200 DMA

$15.82

52W High

$26.98

52W Low

$8.94

5D Low

$11.84

Resistance levels (recent highs)

20d High

$14.91

60d High

$20.88

120d High

$21.47

250d High

$26.98

Next resistance

+13.5%

to 20d High

Dividend Yield

0.00%

P/B 2.8

Crescent Biopharma: quick answers

What stage is Crescent Biopharma in?

As of Oct 22, 2026, Crescent Biopharma (CBIO) is in Stage 3, the topping phase. It entered Stage 3 on Oct 6, 2026 and is in week 3. What the four stages mean

Is Crescent Biopharma in an uptrend?

Its uptrend has stalled. Crescent Biopharma is in Stage 3, the topping phase that follows an advance. It trades 17.0% below its 200-day average, which is rising.

How far is Crescent Biopharma from its 52-week high?

Crescent Biopharma closed at $13.14 on Oct 22, 2026, 51.3% below its 52-week high of $26.98. Its 52-week low is $8.94.

How has Crescent Biopharma performed over the past year?

As of Oct 22, 2026, Crescent Biopharma is up 3.9% over the past year and up 18.6% so far in 2026.

Which sector and industry is Crescent Biopharma in?

Crescent Biopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.